Impact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021

Página do item simplificado
dc.contributor.authorRosadas, Carolina
dc.contributor.authorCosta, Milene
dc.contributor.authorSenna, Kátia
dc.contributor.authorSantos, Marisa
dc.contributor.authorTaylor, Graham P
dc.date.accessioned2025-02-06T15:22:56Z
dc.date.available2025-02-06T15:22:56Z
dc.date.issued2024
dc.description.abstractBackground: Human T-cell lymphotropic virus type 1 (HTLV-1) is a neglected virus that can cause severe dis- ease and be transmitted from mother to child through breastfeeding. Avoidance of breastfeeding prevents 80% of vertical transmission. The United Kingdom (UK) is currently assessing whether HTLV-1-targeted antenatal screening should be implemented. Aim: We aimed to assess the impact and cost-effectiveness of a targeted programme to prevent HTLV-1 vertical trans- mission in England and Wales. Methods: We estimated the number of pregnant women who have high risk of HTLV-1 infection based on their or their partner’s country of birth. With data from 2021, we used a math- ematical model to assess cost-effectiveness of HTLV-1 antenatal screening. We also estimated the annual number of infant infections and the number that could be prevented with screening and intervention. Results: We estimate that ca 99,000 pregnant women in England and Wales have high risk of HTLV-1 infec- tion. In the absence of screening, 74 (range: 25–211) HTLV-1 infections in infants would be expected to occur every year in England and Wales. Implementation of targeted screening would prevent 58 (range: 19–164) infant infections annually. The intervention is effec- tive (incremental 0.00333 quality-adjusted life years (QALY)) and cost-saving (GBP −57.56 (EUR −66.85)). Conclusion: Our findings support implementation of HTLV-1 targeted antenatal screening to reduce vertical transmission from mothers to infants in the UK.
dc.identifier.citationRosadas C, Costa M, Senna K, Santos M, Taylor GP. Impact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021. Euro Surveill. 2024 May;29(22):2300537. doi: 10.2807/1560-7917.ES.2024.29.22.2300537.
dc.identifier.otherDOI: 10.2807/1560-7917.ES.2024.29.22.2300537
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/810
dc.language.isoen
dc.publisherEuro Surveillance
dc.subjectHTLVen
dc.subjectantenatal screeningen
dc.subjectcost-utility analysisen
dc.subjecteconomic analysisen
dc.subjectmaternal healthen
dc.subjectmother-to-child transmissionen
dc.subjectpreventionen
dc.subjectvertical transmission.en
dc.titleImpact and economic analysis of human T-cell lymphotropic virus type 1 (HTLV-1)-targeted antenatal screening, England and Wales, 2021
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Rosadas C et al_Euro Surveill.pdf
Tamanho:
304.99 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente